Does the media favor CBLL or ESTA?

In the previous week, Establishment Labs had 1 more articles in the media than CeriBell. MarketBeat recorded 7 mentions for Establishment Labs and 6 mentions for CeriBell. CeriBell's average media sentiment score of 0.73 beat Establishment Labs' score of 0.53 indicating that CeriBell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Establishment Labs 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CBLL or PLSE?

In the previous week, CeriBell had 4 more articles in the media than Pulse Biosciences. MarketBeat recorded 6 mentions for CeriBell and 2 mentions for Pulse Biosciences. CeriBell's average media sentiment score of 0.73 beat Pulse Biosciences' score of 0.15 indicating that CeriBell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulse Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, CBLL or AXGN?

AxoGen has higher revenue and earnings than CeriBell. AxoGen is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CeriBell $89.06M 7.73 -$53.41M -$1.63 N/A AxoGen $225.21M 10.59 -$15.70M -$0.68 N/A

Is CBLL or AXGN more profitable?

AxoGen has a net margin of -13.36% compared to CeriBell's net margin of -63.51%. AxoGen's return on equity of -8.90% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets CeriBell -63.51% -38.19% -30.92% AxoGen -13.36% -8.90% -6.47%

Does the media refer more to CBLL or AXGN?

In the previous week, AxoGen had 15 more articles in the media than CeriBell. MarketBeat recorded 21 mentions for AxoGen and 6 mentions for CeriBell. CeriBell's average media sentiment score of 0.73 beat AxoGen's score of 0.11 indicating that CeriBell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CBLL or LMAT?

In the previous week, LeMaitre Vascular had 24 more articles in the media than CeriBell. MarketBeat recorded 30 mentions for LeMaitre Vascular and 6 mentions for CeriBell. CeriBell's average media sentiment score of 0.73 beat LeMaitre Vascular's score of 0.16 indicating that CeriBell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LeMaitre Vascular 6 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CBLL or BFLY?

In the previous week, Butterfly Network had 7 more articles in the media than CeriBell. MarketBeat recorded 13 mentions for Butterfly Network and 6 mentions for CeriBell. CeriBell's average media sentiment score of 0.73 beat Butterfly Network's score of 0.47 indicating that CeriBell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Butterfly Network 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

CeriBell (CBLL) Competitors

$18.32 +0.03 (+0.14%)

As of 02:32 PM Eastern

Compare

CBLL vs. ESTA, PLSE, AXGN, LMAT, and BFLY

Should you buy CeriBell stock or one of its competitors? MarketBeat compares CeriBell with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CeriBell include Establishment Labs (ESTA), Pulse Biosciences (PLSE), AxoGen (AXGN), LeMaitre Vascular (LMAT), and Butterfly Network (BFLY). These companies are all part of the "healthcare equipment" industry.

How does CeriBell compare to Establishment Labs?

CeriBell (NASDAQ:CBLL) and Establishment Labs (NASDAQ:ESTA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

In the previous week, Establishment Labs had 1 more articles in the media than CeriBell. MarketBeat recorded 7 mentions for Establishment Labs and 6 mentions for CeriBell. CeriBell's average media sentiment score of 0.73 beat Establishment Labs' score of 0.53 indicating that CeriBell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Establishment Labs	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Establishment Labs has higher revenue and earnings than CeriBell. Establishment Labs is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	7.73	-$53.41M	-$1.63	N/A
Establishment Labs	$229.58M	10.74	-$51.06M	-$1.49	N/A

CeriBell presently has a consensus target price of $22.20, suggesting a potential upside of 22.35%. Establishment Labs has a consensus target price of $93.75, suggesting a potential upside of 11.93%. Given CeriBell's stronger consensus rating and higher probable upside, equities research analysts plainly believe CeriBell is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Establishment Labs has a net margin of -19.05% compared to CeriBell's net margin of -63.51%. CeriBell's return on equity of -38.19% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
Establishment Labs	-19.05%	-218.77%	-12.31%

72.9% of Establishment Labs shares are owned by institutional investors. 17.7% of CeriBell shares are owned by company insiders. Comparatively, 10.0% of Establishment Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CeriBell has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

Summary

Establishment Labs beats CeriBell on 10 of the 17 factors compared between the two stocks.

How does CeriBell compare to Pulse Biosciences?

CeriBell (NASDAQ:CBLL) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

CeriBell has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

CeriBell currently has a consensus price target of $22.20, suggesting a potential upside of 22.35%. Pulse Biosciences has a consensus price target of $32.33, suggesting a potential downside of 17.00%. Given CeriBell's stronger consensus rating and higher possible upside, analysts plainly believe CeriBell is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, CeriBell had 4 more articles in the media than Pulse Biosciences. MarketBeat recorded 6 mentions for CeriBell and 2 mentions for Pulse Biosciences. CeriBell's average media sentiment score of 0.73 beat Pulse Biosciences' score of 0.15 indicating that CeriBell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulse Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CeriBell has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	7.73	-$53.41M	-$1.63	N/A
Pulse Biosciences	$350K	7,703.07	-$72.78M	-$1.10	N/A

Pulse Biosciences has a net margin of 0.00% compared to CeriBell's net margin of -63.51%. CeriBell's return on equity of -38.19% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
Pulse Biosciences	N/A	-86.67%	-73.61%

77.0% of Pulse Biosciences shares are held by institutional investors. 17.7% of CeriBell shares are held by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

CeriBell beats Pulse Biosciences on 11 of the 17 factors compared between the two stocks.

How does CeriBell compare to AxoGen?

CeriBell (NASDAQ:CBLL) and AxoGen (NASDAQ:AXGN) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

CeriBell currently has a consensus target price of $22.20, indicating a potential upside of 22.35%. AxoGen has a consensus target price of $51.00, indicating a potential upside of 14.91%. Given CeriBell's stronger consensus rating and higher possible upside, equities analysts plainly believe CeriBell is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, AxoGen had 15 more articles in the media than CeriBell. MarketBeat recorded 21 mentions for AxoGen and 6 mentions for CeriBell. CeriBell's average media sentiment score of 0.73 beat AxoGen's score of 0.11 indicating that CeriBell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

AxoGen has higher revenue and earnings than CeriBell. AxoGen is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	7.73	-$53.41M	-$1.63	N/A
AxoGen	$225.21M	10.59	-$15.70M	-$0.68	N/A

CeriBell has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, AxoGen has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

AxoGen has a net margin of -13.36% compared to CeriBell's net margin of -63.51%. AxoGen's return on equity of -8.90% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
AxoGen	-13.36%	-8.90%	-6.47%

80.3% of AxoGen shares are held by institutional investors. 17.7% of CeriBell shares are held by insiders. Comparatively, 2.4% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

AxoGen beats CeriBell on 11 of the 17 factors compared between the two stocks.

How does CeriBell compare to LeMaitre Vascular?

CeriBell (NASDAQ:CBLL) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

CeriBell presently has a consensus target price of $22.20, suggesting a potential upside of 22.35%. LeMaitre Vascular has a consensus target price of $110.60, suggesting a potential upside of 37.69%. Given LeMaitre Vascular's higher probable upside, analysts clearly believe LeMaitre Vascular is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
LeMaitre Vascular	0 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.44

LeMaitre Vascular has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	7.73	-$53.41M	-$1.63	N/A
LeMaitre Vascular	$249.60M	7.35	$57.73M	$2.71	29.64

84.6% of LeMaitre Vascular shares are held by institutional investors. 17.7% of CeriBell shares are held by insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CeriBell has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

LeMaitre Vascular has a net margin of 25.02% compared to CeriBell's net margin of -63.51%. LeMaitre Vascular's return on equity of 15.90% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
LeMaitre Vascular	25.02%	15.90%	10.17%

In the previous week, LeMaitre Vascular had 24 more articles in the media than CeriBell. MarketBeat recorded 30 mentions for LeMaitre Vascular and 6 mentions for CeriBell. CeriBell's average media sentiment score of 0.73 beat LeMaitre Vascular's score of 0.16 indicating that CeriBell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LeMaitre Vascular	6 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

LeMaitre Vascular beats CeriBell on 10 of the 16 factors compared between the two stocks.

How does CeriBell compare to Butterfly Network?

CeriBell (NASDAQ:CBLL) and Butterfly Network (NYSE:BFLY) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

CeriBell has a net margin of -63.51% compared to Butterfly Network's net margin of -66.74%. Butterfly Network's return on equity of -33.99% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
Butterfly Network	-66.74%	-33.99%	-22.96%

37.8% of Butterfly Network shares are owned by institutional investors. 17.7% of CeriBell shares are owned by company insiders. Comparatively, 22.0% of Butterfly Network shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CeriBell has higher earnings, but lower revenue than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	7.73	-$53.41M	-$1.63	N/A
Butterfly Network	$112.14M	18.81	-$77.06M	-$0.29	N/A

CeriBell has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Butterfly Network has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market.

CeriBell currently has a consensus price target of $22.20, suggesting a potential upside of 22.35%. Butterfly Network has a consensus price target of $5.56, suggesting a potential downside of 32.86%. Given CeriBell's stronger consensus rating and higher possible upside, equities analysts plainly believe CeriBell is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Butterfly Network	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Butterfly Network had 7 more articles in the media than CeriBell. MarketBeat recorded 13 mentions for Butterfly Network and 6 mentions for CeriBell. CeriBell's average media sentiment score of 0.73 beat Butterfly Network's score of 0.47 indicating that CeriBell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Butterfly Network	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Butterfly Network beats CeriBell on 9 of the 17 factors compared between the two stocks.

Get CeriBell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CBLL vs. The Competition

Export

Metric	CeriBell	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$688.42M	$5.72B	$6.90B	$12.84B
Dividend Yield	N/A	1.78%	2.60%	9.78%
P/E Ratio	-11.13	24.62	281.40	25.46
Price / Sales	7.73	59.52	571.76	79.70
Price / Cash	N/A	32.67	71.79	50.79
Price / Book	4.33	6.06	12.85	6.07
Net Income	-$53.41M	$152.55M	$3.49B	$348.34M
7 Day Performance	2.78%	3.28%	2.38%	3.09%
1 Month Performance	-8.31%	-1.77%	-2.91%	-3.00%
1 Year Performance	41.98%	9.39%	75.57%	20.91%

CeriBell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CBLL CeriBell	2.941 of 5 stars	$18.32 +0.1%	$22.20 +21.2%	+21.3%	$695.36M	$89.06M	N/A	N/A	Positive News Upcoming Earnings
ESTA Establishment Labs	2.6452 of 5 stars	$94.36 +1.7%	$93.75 -0.6%	+107.2%	$2.78B	$211.08M	N/A	1,004	Positive News Earnings Report Analyst Forecast Gap Up
PLSE Pulse Biosciences	1.2974 of 5 stars	$38.26 +1.4%	$32.33 -15.5%	+148.5%	$2.65B	$350K	N/A	140
AXGN AxoGen	2.394 of 5 stars	$45.89 +0.3%	$51.00 +11.1%	+229.6%	$2.47B	$225.21M	N/A	450	Positive News Analyst Revision
LMAT LeMaitre Vascular	4.6575 of 5 stars	$105.72 +2.0%	$112.60 +6.5%	-7.7%	$2.41B	$256.28M	38.92	490	Trending News Earnings Report Analyst Downgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CBLL) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CeriBell (CBLL) Competitors

CBLL vs. ESTA, PLSE, AXGN, LMAT, and BFLY

How does CeriBell compare to Establishment Labs?

Summary

How does CeriBell compare to Pulse Biosciences?

Summary

How does CeriBell compare to AxoGen?

Summary

How does CeriBell compare to LeMaitre Vascular?

Summary

How does CeriBell compare to Butterfly Network?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBLL vs. The Competition

CeriBell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CeriBell (CBLL) Competitors

CBLL vs. ESTA, PLSE, AXGN, LMAT, and BFLY

How does CeriBell compare to Establishment Labs?

Does the media favor CBLL or ESTA?

Which has higher earnings & valuation, CBLL or ESTA?

Do analysts recommend CBLL or ESTA?

Is CBLL or ESTA more profitable?

Do insiders and institutionals have more ownership in CBLL or ESTA?

Which has more volatility & risk, CBLL or ESTA?

Summary

How does CeriBell compare to Pulse Biosciences?

Which has more risk and volatility, CBLL or PLSE?

Do analysts prefer CBLL or PLSE?

Does the media prefer CBLL or PLSE?

Which has better valuation & earnings, CBLL or PLSE?

Is CBLL or PLSE more profitable?

Do insiders & institutionals have more ownership in CBLL or PLSE?

Summary

How does CeriBell compare to AxoGen?

Do analysts recommend CBLL or AXGN?

Does the media refer more to CBLL or AXGN?

Which has stronger earnings & valuation, CBLL or AXGN?

Which has more risk & volatility, CBLL or AXGN?

Is CBLL or AXGN more profitable?

Do insiders & institutionals believe in CBLL or AXGN?

Summary

How does CeriBell compare to LeMaitre Vascular?

Do analysts prefer CBLL or LMAT?

Which has higher valuation & earnings, CBLL or LMAT?

Do insiders and institutionals have more ownership in CBLL or LMAT?

Which has more volatility & risk, CBLL or LMAT?

Is CBLL or LMAT more profitable?

Does the media favor CBLL or LMAT?

Summary

How does CeriBell compare to Butterfly Network?

Is CBLL or BFLY more profitable?

Do insiders & institutionals hold more shares of CBLL or BFLY?

Which has preferable earnings and valuation, CBLL or BFLY?

Which has more risk and volatility, CBLL or BFLY?

Do analysts prefer CBLL or BFLY?

Does the media refer more to CBLL or BFLY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBLL vs. The Competition

CeriBell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools